UPDATE: Needham On CTI BioPharma: Firm Remains Positively Biased For Pacritinib Approval On November 30th For Treatment Of Thrombocytopenic Patients With Advanced Myelofibrosis; Expects Approval By YE21 With 'Projected Sales Of $362M By FY23'